ALK,ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours
Histopathology2015Vol. 69(1), pp. 72–83
Citations Over TimeTop 10% of 2015 papers
Hidetaka Yamamoto, Akihiko Yoshida, Kenichi Taguchi, Kenichi Kohashi, Yui Hatanaka, Atsushi Yamashita, Daisuke Mori, Yoshinao Oda
Abstract
These results suggest that a subset of ALK-negative IMTs have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism, and that the detection of these alterations may be of diagnostic value and helpful for determining promising therapeutic strategies.
Related Papers
- → Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples(2015)26 cited
- → Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas(2009)14 cited
- → A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate(2013)9 cited
- → Ultrarapid detection of sex chromosomes with the use of fluorescence in situ hybridization with direct label dna probes in single human blastomeres, spermatozoa, amniocytes, and lymphocytes(1998)5 cited
- → 45. Case report of unusual ALK gene rearrangement and review of 354 cases of ALK rearrangement study of lung non-small cell carcinoma(2019)